Adalat Cc

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more

Treatment

3 FDA approvals

20 Active Studies for Adalat Cc

What is Adalat Cc

Nifedipine

The Generic name of this drug

Treatment Summary

Nifedipine, also known as BAY a 1040, is a type of calcium channel blocker used to treat high blood pressure. This drug was developed by Bayer in 1972 and approved by the FDA in 1981. It is a first generation dihydropyridine drug and since its development, newer versions have been created that have slower onset and longer lasting effects. The most popular version of this drug is called amlodipine.

Procardia

is the brand name

image of different drug pills on a surface

Adalat Cc Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Procardia

Nifedipine

1981

355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Failed conventional therapy

Helps manage Failed conventional therapy

Vasospastic Angina

Helps manage Vasospastic Angina

Effectiveness

How Adalat Cc Affects Patients

Nifedipine helps to lower blood pressure and increases the amount of oxygen that the heart receives. To keep these effects going, it should be taken three times per day, typically 10-120mg. Some side effects to be aware of include excessive low blood pressure, chest pain, and heart attack.

How Adalat Cc works in the body

Nifedipine works by blocking calcium from entering cells in your arteries and heart. This reduces the pressure in your vessels and increases the oxygen supply to your heart, helping to relieve angina.

When to interrupt dosage

The recommended dosage of Adalat Cc is based on the diagnosed affliction, such as Achalasia, Ureteral Calculus and Hypertensive disease. The amount deviates according to the delivery approach (e.g. Tablet, film coated, extended release or Capsule) delineated in the table below.

Condition

Dosage

Administration

Angina, Stable

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Fissure in Ano

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Vasospastic Angina

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Ureteral Calculi

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Failed conventional therapy

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Proctalgia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Edema

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Altitude Sickness

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Raynaud Disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive Emergency

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Anal sphincter hypertonia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Obstetric Labor, Premature

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Esophageal Achalasia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Hypertension

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Warnings

Adalat Cc has one contraindication, which should be kept in mind when managing any of the conditions mentioned in the table below.

Adalat Cc Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nifedipine may interact with Pulse Frequency

There are 20 known major drug interactions with Adalat Cc.

Common Adalat Cc Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Nifedipine.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Nifedipine.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.

Adalat Cc Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats is 1022mg/kg and in mice is 202mg/kg. Those who overdose may experience low blood pressure, abnormal heart rhythm, and a rapid heartbeat. Treatments for overdose include monitoring vital signs, raising the patient's arms and legs, and administering fluids, vasopressors, and calcium.

image of a doctor in a lab doing drug, clinical research

Adalat Cc Novel Uses: Which Conditions Have a Clinical Trial Featuring Adalat Cc?

101 active clinical trials are currently underway to discern if Adalat Cc can be used to alleviate Achalasia, Hypertensive Emergency and Anal Fissure.

Condition

Clinical Trials

Trial Phases

Obstetric Labor, Premature

2 Actively Recruiting

Not Applicable

Pulmonary Edema

0 Actively Recruiting

Hypertensive disease

35 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Angina, Stable

0 Actively Recruiting

Esophageal Achalasia

0 Actively Recruiting

Altitude Sickness

1 Actively Recruiting

Early Phase 1

Raynaud Disease

1 Actively Recruiting

Phase 4

Pulmonary Hypertension

34 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Proctalgia

0 Actively Recruiting

Hypertensive Emergency

0 Actively Recruiting

Fissure in Ano

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Anal sphincter hypertonia

0 Actively Recruiting

Ureteral Calculi

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

Adalat Cc Reviews: What are patients saying about Adalat Cc?

5

Patient Review

5/26/2008

Adalat Cc for High Blood Pressure

This medication has been incredibly helpful for me.

4.7

Patient Review

9/17/2009

Adalat Cc for Type of Angina Where Chest Pain Occurs at Rest

This lowered my blood pressure for about five hours after taking it, which is good. However, I would prefer if it were more consistent throughout the day and night.

4.7

Patient Review

10/6/2016

Adalat Cc for High Blood Pressure

This drug works well for me in conjunction with Altace. I get the occasional cramping in my lower legs but no other negative side effects that I've noticed.

4.3

Patient Review

9/21/2009

Adalat Cc for High Blood Pressure

I've been on this medication for over six years now. I had originally started because of severe chest pains that were frequent and hospitalizing. After some testing, it was determined that I didn't have any blockages, but rather spasms in my arteries. This medication has helped to almost entirely remove the pain and severity when they do occur.

4.3

Patient Review

12/4/2007

Adalat Cc for High Blood Pressure

I unfortunately had an allergic reaction to the medication. My baby has also been experiencing diarrhea since I started taking it.

4

Patient Review

6/15/2011

Adalat Cc for High Blood Pressure

AdalatXL - 30 mg. was very effective for lowering my blood pressure, to the point where my doctor no longer prescribed it because my readings were too low. However, I began experiencing protein in my urine and chest congestion.

4

Patient Review

7/1/2012

Adalat Cc for Type of Angina Where Chest Pain Occurs at Rest

I was on this medication for a little over two years when my angina first developed. At that time, it was classified as "stable." Unfortunately, this past March it progressed to "unstable" angina. I had an angiogram and there's no blockage. The doctors think the spasms are in the muscles around my heart. Once my angina turned unstable, I had to switch to a different medication because this one didn't work anymore.

4

Patient Review

10/20/2007

Adalat Cc for High Blood Pressure

3.7

Patient Review

10/13/2009

Adalat Cc for High Blood Pressure

I constantly experience muscle cramps and can only sleep for two hours at a time. I also have to use the restroom frequently.

3.7

Patient Review

7/11/2009

Adalat Cc for High Blood Pressure

This treatment helped me with my insomnia, but I found that I had to wake up more often to urinate at night.

3.3

Patient Review

7/26/2012

Adalat Cc for High Blood Pressure

I've been on this medication for years and have only recently started experiencing negative side effects. These include an itchy rash, hot flashes, swollen legs and ankles. I am seeing my doctor tomorrow to get this sorted out and will be finding a new one afterwards.

3

Patient Review

9/28/2010

Adalat Cc for High Blood Pressure

While this medication does effectively control blood pressure, it unfortunately comes with a host of other irritating side effects, such as swelling, flushing, heartburn, and tingling in hands and feet. Additionally, I experienced hair loss while taking this medication. It's frustrating that all hypertension medications seem to come with such a long list of negative side effects.

2.3

Patient Review

12/2/2007

Adalat Cc for High Blood Pressure

I'm concerned about the warnings for use of this medication. May cause kidney damage, reduce white cells, destroy cell to cell communication and increase risk to cancer. I just completed treatments for prostrate cancer. Only med that seems to control high blood press.

1.3

Patient Review

3/2/2008

Adalat Cc for Occasional Numbness, Prickling, or Tingling of Fingers and Toes

My blood pressure has gone down to 125/85.

1

Patient Review

7/7/2008

Adalat Cc for High Blood Pressure

I've been using Adalat CC for eight years now and I'm really happy with it. No negative side effects that I know of, and my blood pressure is great.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adalat cc

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does CC stand for in Adalat CC?

"Calcium channel blocking agents are a type of drug that block calcium from entering cells. This can help to reduce blood pressure and treat heart conditions."

Answered by AI

What is the difference between Procardia XL and Adalat CC?

"The main difference between the two drugs is how they release nifedipine. Procardia XL releases nifedipine through an osmotic pump delivery system, while Adalat CC releases it by successively dissolving layers."

Answered by AI

Who makes Adalat CC?

"Aurobindo Pharma's nifedipine extended-release tablets have been approved by the Food and Drug Administration in three dosage strengths. The product, a generic of Alvogen's Adalat CC, is indicated as a treatment for hypertension. Aurobindo's generic will be available in dosage strengths of 30-, 60- and 90mg."

Answered by AI

What are the side effects of Adalat CC?

"anxiety

Perhaps you've been experiencing some side effects from the medication you've been taking. These may include headache, dizziness, fatigue, tiredness, drowsiness, flushing, sleep problems, vivid or abnormal dreams, or anxiety."

Answered by AI

Clinical Trials for Adalat Cc

Image of Vanderbilt University Medical Center in Nashville, United States.

Nicotinamide Riboside for Pulmonary Hypertension

18 - 85
All Sexes
Nashville, TN

Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected. This study is based on a new approach that uses advanced computer methods to analyze a patient's unique biology and identify potential drug targets. Using this method, we identified nicotinamide riboside (NR) as a promising option for people with CPH. NR is a form of vitamin B3 that helps the body make NAD⁺, a substance essential for how cells produce energy and stay healthy. NAD⁺ plays an important role in how heart and blood vessel cells function. Previous research in animals suggests NR may help improve blood vessel changes in the lungs and support heart function. NR has also shown potential benefits in human studies related to cell energy, mitochondrial health, and reducing oxidative stress. In this study, NR is used only as a dietary supplement that supports normal body processes, not as a proven treatment. The investigators will conduct a small, carefully controlled study in which participants receive NR and a placebo at different times. The goal is to understand how NR affects biological and biochemical markers in the body, not to test whether it improves symptoms or outcomes. Any clinical measurements are included only to help interpret the biological effects.

Recruiting
New This Month

Vanderbilt University Medical Center

Evan L Brittain, MD

Image of Hāmākua-Kohala Health Center in Honokaa, United States.

Produce Prescription for High Blood Pressure

18+
All Sexes
Honokaa, HI

This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness. The study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and/or the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities. To test the effectiveness of the added CHW support, there will be two groups of participants: Group 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges. Group 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW. The investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes. Upon providing informed consent and enrolling into the program, produce prescription program participants will: * Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months. * Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure. * Answer surveys about their demographic background, health habits, diet, and culture. * Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer. * Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program. * Group 2 will receive monthly reminders to use their vouchers but no CHW meetings. After the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.

Waitlist Available
Has No Placebo

Hāmākua-Kohala Health Center (+2 Sites)

Have you considered Adalat Cc clinical trials?

We made a collection of clinical trials featuring Adalat Cc, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Have you considered Adalat Cc clinical trials?

We made a collection of clinical trials featuring Adalat Cc, we think they might fit your search criteria.
Go to Trials
Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Recruiting
Has No Placebo

U Health (+5 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Adalat Cc clinical trials?

We made a collection of clinical trials featuring Adalat Cc, we think they might fit your search criteria.
Go to Trials